MX2010004195A - Trans-clomifeno para el sindrome metabolico. - Google Patents

Trans-clomifeno para el sindrome metabolico.

Info

Publication number
MX2010004195A
MX2010004195A MX2010004195A MX2010004195A MX2010004195A MX 2010004195 A MX2010004195 A MX 2010004195A MX 2010004195 A MX2010004195 A MX 2010004195A MX 2010004195 A MX2010004195 A MX 2010004195A MX 2010004195 A MX2010004195 A MX 2010004195A
Authority
MX
Mexico
Prior art keywords
clomiphene
metabolic syndrome
trans
antiestrogen
subject
Prior art date
Application number
MX2010004195A
Other languages
English (en)
Spanish (es)
Inventor
Andre Van As
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40023452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MX2010004195A publication Critical patent/MX2010004195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2010004195A 2007-10-16 2008-09-05 Trans-clomifeno para el sindrome metabolico. MX2010004195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98033407P 2007-10-16 2007-10-16
PCT/US2008/075433 WO2009051908A1 (en) 2007-10-16 2008-09-05 Trans-clomiphene for metabolic syndrome

Publications (1)

Publication Number Publication Date
MX2010004195A true MX2010004195A (es) 2010-06-02

Family

ID=40023452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004195A MX2010004195A (es) 2007-10-16 2008-09-05 Trans-clomifeno para el sindrome metabolico.

Country Status (24)

Country Link
US (2) US8372887B2 (enExample)
EP (2) EP2211848A1 (enExample)
JP (4) JP5558358B2 (enExample)
KR (1) KR101493472B1 (enExample)
CN (2) CN102940619A (enExample)
AR (1) AR069541A1 (enExample)
BR (1) BRPI0818637A2 (enExample)
CA (3) CA2866905C (enExample)
CL (1) CL2008002999A1 (enExample)
CO (1) CO6270215A2 (enExample)
CR (1) CR11418A (enExample)
EA (2) EA022760B1 (enExample)
EC (1) ECSP10010106A (enExample)
ES (1) ES2718912T3 (enExample)
IL (1) IL205053A (enExample)
ME (1) ME00996B (enExample)
MX (1) MX2010004195A (enExample)
MY (1) MY150082A (enExample)
NI (1) NI201000053A (enExample)
NZ (2) NZ591955A (enExample)
SG (1) SG185311A1 (enExample)
TW (1) TW200918093A (enExample)
UA (1) UA96076C2 (enExample)
WO (1) WO2009051908A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
TWI458478B (zh) * 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
CA2811258C (en) * 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
MX2014009322A (es) * 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
SG10201704820SA (en) 2012-08-21 2017-07-28 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
WO2016089904A1 (en) * 2014-12-02 2016-06-09 Repros Therapeutics Inc. Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases
EP3167869B1 (en) 2015-11-16 2025-02-12 Capsugel Belgium NV Tamperproof oral dosage form
EP3167870B1 (en) 2015-11-16 2024-01-03 Capsugel Belgium NV Tamperproof oral dosage form
RU2611936C1 (ru) * 2016-02-16 2017-03-01 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Д. Гольдберга" Способ моделирования гипогонадизма, вызванного метаболическими нарушениями
JP2019506425A (ja) * 2016-02-25 2019-03-07 アスペン パーク ファーマシューティカルズ，インコーポレイティド クロミフェン異性体の経口剤形および続発性性腺機能低下症を治療するために経口剤形を使用する方法
EP3493794A4 (en) * 2016-08-04 2020-05-06 University of Iowa Research Foundation USE OF SWELL1 INHIBITORS AND MODULATORS FOR TREATING TYPE 2 DIABETES AND ADIPOSITAS
US20250152525A1 (en) * 2023-11-09 2025-05-15 Woody's Medical LLC Compositions and methods for the treatment of testosterone deficiency in males

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
BE637389A (enExample) 1962-09-13
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
DE2658307C2 (de) 1976-12-22 1979-03-15 Klinge Pharma Gmbh & Co, 8000 Muenchen Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IE58417B1 (en) 1984-04-27 1993-09-22 Ici Plc Chemical derivatives
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US5352795A (en) 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3762617D1 (de) 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8714013D0 (en) 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1993023374A1 (fr) 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JP2964871B2 (ja) 1994-04-20 1999-10-18 ノーリツ鋼機株式会社 ネガマスク装置
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
WO1995035093A1 (en) 1994-06-17 1995-12-28 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
CA2228610C (en) 1995-08-17 2008-06-03 Heidi Rolfes Controlled release products
HUP9902683A3 (en) 1996-01-11 2001-08-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
AU1367197A (en) 1996-01-11 1997-08-01 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5985910A (en) 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JP4496316B2 (ja) 1997-04-03 2010-07-07 エーザイ インコーポレイテッド 生分解性テレフタレートポリエステル−ポリホスフェートポリマー、組成物、物品、並びにその製造及び使用方法
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ZA982819B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
ZA982818B (en) 1997-04-09 1999-10-04 Lilly Co Eli Prevention of breast cancer using selective estrogen receptor modulators.
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
CA2298651A1 (en) 1997-08-07 1999-02-18 Jeffrey Alan Dodge 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6069153A (en) 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
NZ510201A (en) 1998-07-30 2002-10-25 Stoller Ets Treatment of plants with salicylic acid and organic amines
DE69935335T2 (de) 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
ATE315033T1 (de) 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP5184727B2 (ja) 1999-06-11 2013-04-17 ワトソン ファーマシューティカルズ， インコーポレイテッド 女性への非経口アンドロゲンステロイドの投与
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6340774B1 (en) 2000-01-31 2002-01-22 The Board Of Trustees Of The Leland Stanford Junior University Non-steroidal estrogen-receptor antagonists
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001098322A1 (en) 2000-06-22 2001-12-27 Northeastern University Novel steroidal antiestrogens and antiandrogens and uses thereof
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1417169A2 (en) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
JP2005502654A (ja) 2001-08-13 2005-01-27 メルク　エンド　カムパニー　インコーポレーテッド 選択的エストロゲン受容体調節剤
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
ATE481397T1 (de) 2002-04-24 2010-10-15 Merck Sharp & Dohme Modulatoren des östrogenrezeptors
EP1776098A1 (en) * 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
WO2006084153A2 (en) * 2005-02-04 2006-08-10 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
US20080306035A1 (en) 2005-08-05 2008-12-11 Repros Therapeutics Inc. Methods and Compositions for Treating Female Infertility Using Clomiphene
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.

Also Published As

Publication number Publication date
CA2806526A1 (en) 2009-04-23
CN102940619A (zh) 2013-02-27
US20090099265A1 (en) 2009-04-16
CA2702710A1 (en) 2009-04-23
UA96076C2 (en) 2011-09-26
CA2866905C (en) 2016-04-19
JP2016040328A (ja) 2016-03-24
IL205053A0 (en) 2010-11-30
EP2211848A1 (en) 2010-08-04
US20120022167A1 (en) 2012-01-26
IL205053A (en) 2014-09-30
JP2017160273A (ja) 2017-09-14
EP2826475B1 (en) 2019-03-20
CR11418A (es) 2010-08-24
NZ591955A (en) 2011-10-28
EA022760B1 (ru) 2016-02-29
EA201200968A1 (ru) 2012-12-28
JP2011500690A (ja) 2011-01-06
EA201070477A1 (ru) 2010-10-29
BRPI0818637A2 (pt) 2015-04-07
EP2826475A1 (en) 2015-01-21
US8372887B2 (en) 2013-02-12
EA017385B1 (ru) 2012-12-28
CA2702710C (en) 2013-05-07
AU2008314538A1 (en) 2009-04-23
CA2806526C (en) 2014-12-30
SG185311A1 (en) 2012-11-29
KR20100091168A (ko) 2010-08-18
KR101493472B1 (ko) 2015-02-16
JP2014185160A (ja) 2014-10-02
ECSP10010106A (es) 2010-06-29
CN101896174B (zh) 2012-10-31
NI201000053A (es) 2013-01-16
CN101896174A (zh) 2010-11-24
JP5856652B2 (ja) 2016-02-10
HK1150023A1 (en) 2011-10-28
CA2866905A1 (en) 2009-04-23
JP5558358B2 (ja) 2014-07-23
US8377991B2 (en) 2013-02-19
CO6270215A2 (es) 2011-04-20
MY150082A (en) 2013-11-29
ME00996B (me) 2012-10-20
AR069541A1 (es) 2010-02-03
TW200918093A (en) 2009-05-01
NZ585389A (en) 2011-10-28
CL2008002999A1 (es) 2009-03-20
ES2718912T3 (es) 2019-07-05
WO2009051908A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MY150082A (en) Trans-clomiphene for metabolic syndrome
DE602007004324D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
MX2008013484A (es) Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1.
MX342684B (es) Regimen de dosificacion escalante para efectuar la perdida de peso y el tratamiento de obesidad.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
TNSN08432A1 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
EA201100503A1 (ru) Глюкозидные производные и их применения
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
EA201170703A1 (ru) Производные адамантилбензамида
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
IN2012DN00639A (enExample)
TW200942524A (en) Novel aminomethyl benzene derivatives
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
ZA201008160B (en) Compositions for the treatment of hair loss
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
MY173722A (en) Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
NZ622993A (en) Combination therapy for the treatment of diabetes
UA103767C2 (ru) Карбоксамидные соединения для лечения метаболических расстройств

Legal Events

Date Code Title Description
FG Grant or registration